Itching

SAN DIEGO — Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

ORLANDO — Itching in older patients should not be dismissed as simply dry skin, but rather approached as a complex problem involving numerous causes, according to a speaker at the American Academy of Dermatology Annual Meeting.

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor receptor inhibitor cancer therapy, according to a Hoth Therapeutics press release detailing phase 2a interim data.

BOSTON — Chronic hand eczema can interfere with daily activities and have a significant negative impact on quality of life, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Patients with chronic inducible urticaria saw improvements in itch and wheals with barzolvolimab in 12 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Chronic spontaneous urticaria symptoms improved with 1 week of remibrutinib treatment, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

A topical cream containing cannabis “significantly reduced the severity of itching” symptoms in patients with chronic kidney disease-related pruritus, according to published data.

Sirolimus may be a safe and effective alternative for patients with chronic spontaneous urticaria who do not respond to other treatments, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress.

Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.